Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hepato-Biliary-Pancreatic Sciences
Published in: Journal of Hepato-Biliary-Pancreatic Sciences 6/2010

01-11-2010 | Original article

Muromonab-CD3 therapy for refractory rejections after liver transplantation: a single-center experience during two decades in Japan

Authors: Daisuke Ueda, Tomohide Hori, Justin H. Nguyen, Shinji Uemoto

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 6/2010

Login to get access

Abstract

Background/purpose

Refractory rejections still occur in the liver transplantation (LT) field. The aim of this study was to investigate significant factors for the introduction of therapy with muromonab-CD3 (MCD3) after LT.

Methods

A total of 1415 LT patients were retrospectively evaluated, and 11 of the recipients received MCD3 therapy because of steroid-resistant rejections. The clinical factors before LT and before MCD3 therapy were investigated.

Results

The recipients were retrospectively divided into two groups based on responses to MCD3 therapy, including their clinical courses after MCD3 therapy and their outcomes. The MCD3 therapy had positive effects in LT recipients with the following four factors: low score of model for end-stage liver disease or pediatric end-stage liver disease; earlier time point of the first incidence of rejection; more frequent steroid pulse therapy (SPT) within 2 weeks after LT; and the expression of CD3 in the peripheral blood before MCD3 introduction.

Conclusion

Optimal induction of MCD3 triggered recovery from refractory rejections, especially in LT recipients in a stable condition, but not in those in a critical or compromised condition.
Literature
1.
Egawa H, Ohdan H, Haga H, Tsuruyama T, Oike F, Uemoto S, et al. Current status of liver transplantation across ABO blood-type barrier. J Hepatobiliary Pancreat Surg. 2008;15:131–8.CrossRefPubMed
2.
Yoshizawa A, Sakamoto S, Ogawa K, Kasahara M, Uryuhara K, Oike F, et al. New protocol of immunosuppression for liver transplantation across ABO barrier: the use of Rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc. 2005;37:1718–9.CrossRefPubMed
3.
Ueda M, Oike F, Ogura Y, Uryuhara K, Fujimoto Y, Kasahara M, et al. Long-term outcomes of 600 living donor liver transplants for pediatric patients at a single center. Liver Transpl. 2006;12:1326–36.CrossRefPubMed
4.
Ogura Y, Kaihara S, Haga H, Kozaki K, Ueda M, Oike F, et al. Outcomes for pediatric liver retransplantation from living donors. Transplantation. 2003;76:943–8.CrossRefPubMed
5.
Martin SR, Atkison P, Anand R, Lindblad AS. Studies of Pediatric Liver Transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. Pediatr Transplant. 2004;8:273–83.CrossRefPubMed
6.
Margarit C, Rimola A, Gonzalez-Pinto I, Cuervas-Mons V, Edo A, Andreu H, et al. Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. Transpl Int. 1998;11(Suppl 1):S260–6.PubMed
7.
Sakamoto S, Haga H, Egawa H, Kasahara M, Ogawa K, Takada Y, et al. Living donor liver transplantation for acute liver failure in infants: the impact of unknown etiology. Pediatr Transplant. 2008;12:167–73.CrossRefPubMed
8.
Alonso EM, Piper JB, Echols G, Thistlethwaite JR, Whitington PF. Allograft rejection in pediatric recipients of living related liver transplants. Hepatology. 1996;23:40–3.CrossRefPubMed
9.
Joseph JT, Kingsmore DB, Junor BJ, Briggs JD, Mun Woo Y, Jaques BC, et al. The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant. 2001;15:221–7.CrossRefPubMed
10.
Blakolmer K, Jain A, Ruppert K, Gray E, Duquesnoy R, Murase N, et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation. 2000;69:2330–6.CrossRefPubMed
11.
Blakolmer K, Seaberg EC, Batts K, Ferrell L, Markin R, Wiesner R, et al. Analysis of the reversibility of chronic liver allograft rejection implications for a staging schema. Am J Surg Pathol. 1999;23:1328–39.CrossRefPubMed
12.
Hooks MA, Wade CS, Millikan WJ Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 1991;11:26–37.PubMed
13.
Hori T, Egawa H, Takada Y, Oike F, Ogura Y, Ogawa K, et al. Fatal impact of lymphocyte cross-matching upon humoral rejection after adult living related liver transplantation. Transpl Int. 2010;23:338–340
14.
Mazariegos GV, Salzedas AA, Zavatsky J, Sindhi R, Parizhskaya M, McGhee W, et al. Long term management of liver transplant rejection in children. BioDrugs. 2000;14:31–48.CrossRefPubMed
15.
Solomon H, Gonwa TA, Mor E, Holman MJ, Gibbs J, Watemberg I, et al. OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation. 1993;55:87–91.CrossRefPubMed
16.
Goldstein G, Kremer AB, Barnes L, Hirsch RL. OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients. J Pediatr. 1987;111:1046–50.CrossRefPubMed
17.
Todd PA, Brogden RN. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989;37:871–99.CrossRefPubMed
18.
Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25:658–63.
19.
Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology. 2000;31:792–9.CrossRefPubMed
20.
Neil DA, Hubscher SG. Histologic and biochemical changes during the evolution of chronic rejection of liver allografts. Hepatology. 2002;35:639–51.CrossRefPubMed
21.
Austin GL, Sasaki AW, Zaman A, Rabkin JM, Olyaei A, Ruimy R, et al. Comparative analysis of outcome following liver transplantation in US veterans. Am J Transplant. 2004;4:788–95.CrossRefPubMed
22.
Habib S, Berk B, Chang CC, Demetris AJ, Fontes P, Dvorchik I, et al. MELD and prediction of post-liver transplantation survival. Liver Transpl. 2006;12:440–7.CrossRefPubMed
23.
Gayowski T, Marino IR, Singh N, Doyle H, Wagener M, Fung JJ, et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation. 1998;65:499–504.CrossRefPubMed
24.
Oguma S, Belle S, Starzl TE, Demetris AJ. A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology. 1989;9:204–9.CrossRefPubMed
25.
Gupta P, Kaufman S, Fishbein TM. Sirolimus for solid organ transplantation in children. Pediatr Transplant. 2005;9:269–76.CrossRefPubMed
26.
Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342:1514–6.CrossRefPubMed
27.
Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M, et al. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transpl Immunol. 1995;3:212–21.CrossRefPubMed
28.
Caballero A, Fernandez N, Lavado R, Bravo MJ, Miranda JM, Alonso A. Tolerogenic response: allorecognition pathways. Transpl Immunol. 2006;17:3–6.CrossRefPubMed
29.
Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol. 2002;10:101–8.CrossRefPubMed
Metadata
Title
Muromonab-CD3 therapy for refractory rejections after liver transplantation: a single-center experience during two decades in Japan
Authors
Daisuke Ueda
Tomohide Hori
Justin H. Nguyen
Shinji Uemoto
Publication date
01-11-2010
Publisher
Springer Japan
Published in
Journal of Hepato-Biliary-Pancreatic Sciences / Issue 6/2010
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI
https://doi.org/10.1007/s00534-010-0288-y

Other articles of this Issue 6/2010

Journal of Hepato-Biliary-Pancreatic Sciences 6/2010 Go to the issue

Original article

Expression of MUC5AC, an early marker of pancreatobiliary cancer, is regulated by DNA methylation in the distal promoter region in cancer cells

Topics

For which type of chronic pancreatitis is the “Hamburg procedure” indicated?

Original article

Pancreatobiliary reflux and the length of a common channel

Topics

Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein: techniques and its significance

Topics

Distal pancreatectomy with preservation of the spleen

Topics

Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms